Loading stock data…
Bicara Therapeutics Inc. (BCAX)
$23.71+0.54 (+2.33%)
Market ClosedLast close Sep 8
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bicara Therapeutics Inc. in the Healthcare sector is trading at $23.71 with a market capitalization of $1.3B. Wall Street consensus targets $34.54 (13 analysts), implying a +45.7% move over the next 12 months. The stock is currently 23% below its 52-week high of $30.99, remaining 12.6% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +45.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$60.24M↓ | -$41.12M↓ | -$40.68M↓ | -$32.02M↑ | -$41.79M |
| Net Income | -$56.21M↓ | -$37.39M↓ | -$36.33M↓ | -$27.39M↑ | -$36.85M |
Peer Comparison
JNJUNHPFE
Fundamentals
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal g...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.31B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-30.61%
Volume
Today's trading volume
709,587
Recent News
Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul
On August 11, Bicara Therapeutics (NASDAQ:BCAX) used its second-quarter earnings call to deliver two headlines at once. CEO Claire Mazumdar announced she will step into a Vice Chair and Strategic Adviser role at the start of next year, handing the top job to President and Chief Operating Officer Ryan Cohlhepp. That handoff arrives just as […]
Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript
Cash runway extends to 2029 as ficerafusp alfa advances toward interim analysis.
Leadership Shake-Up And Ficerafusp Alfa Milestone Timeline Might Change The Case For Investing In Bicara Therapeutics (BCAX)
Bicara Therapeutics recently reported second-quarter 2026 results showing a wider net loss of US$55.44 million and higher loss per share, alongside filing a US$19.41 million employee stock offering shelf registration. At the same time, the company outlined a broad leadership reshuffle and ongoing preparation for possible commercialization of ficerafusp alfa, as its pivotal FORTIFI-HN01 trial in HPV-negative head and neck cancer advances toward an interim readout expected in mid-2027. We’ll...
Bicara Therapeutics' Cancer Study On Track for 2026 Enrollment, Wedbush Says
Bicara Therapeutics (BCAX) pivotal Fortifi-HN01 study in first-line recurrent/metastatic HPV-negativ
Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary
Moby summary of Bicara Therapeutics Inc. Common Stock's Q2 2026 earnings call